Full results from Kids B-LONG Alprolix® paediatric study to be released for the first time. Interim findings to be presented from ASPIRE, an open label extension study with Eloctate®/Elocta® in adults and children with haemophilia A
Fully automated instrument speeds workflow for fast, efficient results
Rasilez (aliskiren), the first new type of high blood pressure medicine in more than a decade, has been approved for use in Japan. Rasilez directly inhibits renin, an enzyme that triggers a process leading to high blood pressure and organ damage. The Ministry of Health, Labour and Welfare (MHLW) in Japan approved Rasilez for the treatment of high blood pressure alone or in combination with other high blood pressure medicines.